Prevention of Systemic Lupus Erythematosus in Autoimmune BXSB Mice by a Transgene Encoding I-E α Chain

By Ramón Merino,* Masahiro Iwamoto,* Liliane Fossati,* Pedro Muniesa,† Kimi Araki,* Satoru Takahashi,* Joaquín Huarte,‡ Ken-Ichi Yamamura,§ Jean-Dominique Vassalli,‡ and Shozo Izui*

From the Departments of *Pathology and †Morphology, Centre Médical Universitaire, University of Geneva, 1211 Geneva 4, Switzerland; and the §Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine, Kumamoto 862, Japan

Summary
Males from the BXSB murine strain (H-2b) spontaneously develop an autoimmune syndrome with features of systemic lupus erythematosus (SLE), which results in part from the action of a mutant gene (Yaa) located on the Y chromosome. Like other H-2b mice, the BXSB strain does not express the class II major histocompatibility complex antigen, I-E. Here we report that the expression of I-E (Ecα) in BXSB males bearing an Ecα transgene prevents hypergammaglobulinemia, autoantibody production, and subsequent autoimmune glomerulonephritis. These transgenic mice bear on the majority of their B cells not only I-E molecules, but also an I-E α chain–derived peptide presented by a higher number of I-Ab molecules, as recognized by the Y-Ae monoclonal antibody. The I-E+ B cells appear less activated in vivo than the I-E− B cells, a minor population. This limited activation of the I-E+ B cells does not reflect a functional deficiency of this cell population, since it can be stimulated to IgM production in vitro by lipopolysaccharides at an even higher level than the I-E− B cell population. The development of the autoimmune syndrome in the transgenic and nontransgenic bone marrow chimeric mice argues against the possibility that the induction of regulatory T cells or clonal deletion of potential autoreactive T cells as a result of I-E expression is a mechanism of the protection conferred by the Ecα transgene. We propose a novel mechanism by which the Ecα transgene protects BXSB mice against SLE: overexpression of I-E α chains results in the generation of excessive amounts of a peptide displaying a high affinity to the I-Ab molecule, thereby competing with pathogenic autoantigen–derived peptides for presentation by B lymphocytes and preventing their excessive stimulation.

The BXSB mouse strain spontaneously develops a progressive and lethal autoimmune disease, similar to human SLE, which affects male animals much earlier than females (1, 2). Cell transfer and Y chromosome transfer studies have clearly demonstrated that the Y chromosome-linked autoimmune acceleration (Yaa) gene present in the Y chromosome of the BXSB strain is responsible, in mice predisposed to autoimmune diseases, for the accelerated autoimmune abnormalities and immunopathological lesions (3–6). In addition, it has been demonstrated that the MHC genes play a critical role in the development of SLE-like autoimmune syndrome in BXSB mice (7) and in their F1 hybrids with NZB mice (Merino, R., M. Iwamoto, and S. Izui, manuscript in preparation): the H-2b haplotype appears to be associated with the development of the autoimmune disease, whereas the H-2d haplotype protects against this disease. Since BXSB and (NZB × BXSB)F1 mice bearing the H-2d haplotype do not express one of the class II MHC antigens, I-E (because of the deletion of the promoter region of the Ecα gene [8]), the inhibitory effect of the H-2d haplotype may in part be related to the expression of the I-E molecule. In fact, it has been shown that I-E molecules could exhibit a suppressive activity on immune responses (9), and more recently the expression of I-E molecules through an I-E α chain transgene was found to result in the prevention of autoimmune diabetes in NOD (I-E−) mice (10–13). In the present study, we found that the expression of a transgene encoding the I-E α chain, Ecα, is highly protective against the development of the lupuslike autoimmune disease in BXSB mice, and defined the possible protective mechanism(s) conferred by the expression of this transgene.
Materials and Methods

Generation of BXSB Ec\textsuperscript{d} Transgenic and BXSB.Igh\textsuperscript{a} Congenic Mice. BXSB mice were purchased from The Jackson Laboratories (Bar Harbor, ME). A 14-kb SacII/XhoI fragment containing the entire Ec\textsuperscript{d} gene sequence (14) was microinjected into fertilized eggs of BXSB mice, as described (15). Mice were screened for the transgene by the surface staining of PBMC using an anti-I-E mAb, Y-17 (16), as described below. BXSB.Igh\textsuperscript{a} congenic mice were established by transfer of the Igh\textsuperscript{a} gene complex of the BC20/1cr strain as follows: BXSB female males were mated with BC20/1cr males, male offspring which carry the Igh\textsuperscript{a} allotype, as determined by ELISA (described below), were then backcrossed with BXSB females for 11 generations. Then, females carrying the Igh\textsuperscript{a} allotype were mated with BXSB males to introduce the Igh\textsuperscript{a} gene. The BXSB.Igh\textsuperscript{a} novel strain was obtained by mating female and male BXSB Igh\textsuperscript{b} heterozygotes at the 12th backcross generation.

Southern Blot Analysis. Total RNA was extracted, using the guanidine isothiocyanate/CsCl method (19), from spleen, thymus, lymph nodes, liver, kidneys, lungs, and brain of BXSB mice. RNA (30 μg) were electrophoresed on a 1% agarose gel, transferred to a nylon membrane (GeneScreen Plus; Du Pont Co., Boston, MA) as described (17). Hybridization was carried out under high stringency with a 32P-labeled 2.6-kb Sall fragment containing the first exon of the Ec\textsuperscript{d} gene (18), which recognizes two 1.9 and 2.9-kb fragments of the injected Ec\textsuperscript{d} gene and a 4.2-kb fragment of the endogenous defective Ec\textsuperscript{d} gene in Sacl-digested DNA (see Fig. 1 A).

Northern Blot Analysis. Total RNA was extracted, using the guanidine isothiocyanate/CsCl method (19), from spleen, thymus, lymph nodes, liver, kidneys, lungs, and brain of BXSB mice. RNA (30 μg) were electrophoresed on a 1% agarose gel, transferred to nylon membrane, and hybridized with a 32P-labeled 3.5-kb Sall fragment containing exons 2, 3, and 4 of the Ec\textsuperscript{d} gene (18) or 32P-labeled cDNA corresponding to β-actin.

Cytofluorometric Analysis. The expression of I-E and/or I-A molecules in peripheral blood and spleen cells was analyzed by staining first with FITC-conjugated anti-mouse μ chain mAb (LO-MM-9) (20), and then incubating with biotinylated anti-I-E (Y-17) and/or anti-I-A\textsuperscript{a} (Y-3P) mAb (21), followed by PE-conjugated avidin (Caltag Laboratories, San Francisco, CA) and analyzed with a FACSscan (Becton Dickinson & Co., Mountain View, CA). The expression of the I-A\textsuperscript{a}:Ec\textsuperscript{d} peptide complexes, recognized by the Y-2e mAb (22, 23), was determined by two different staining procedures. First, spleen cells were first stained with FITC-conjugated anti–mouse μ chain mAb (LO-MM-9), and then incubated with biotinylated Y-2e mAb, followed by PE-conjugated avidin. Second, spleen cells were first stained with FITC-labeled anti-I-E (Y-17) mAb, then with PE-conjugated goat anti–mouse μ chain Abs (Caltag Laboratories), and incubated with biotinylated Y-2e mAb, followed by Streptavidin-RED670 (Gibco BRL, Gaithersburg, MD). The expression of V\textsuperscript{β} segments of TCR in Thy-1\textsuperscript{+} lymph node cells was analyzed as described previously (7). Monocytes in peripheral blood were enumerated using anti-Mac-1 mAb (M1/70) (24) followed by FITC-conjugated goat anti–rat IgG Abs. Surface IgM and IgG\textsuperscript{b} positive cells in peripheral blood from bone marrow chim-meric mice were stained with biotinylated mAb, RS-3.1 (anti-IgM\textsuperscript{b}) (25), and MB86 (anti-IgM\textsuperscript{b}) (26), followed by PE-conjugated avidin.

Histopathology. Samples of all major organs were obtained at autopsy, and histological sections were stained with either the periodic acid-Schiff reagent or with hematoxylin eosin. Glomerulonephritis was scored on a 0-4 scale based on the intensity and extent of histopathological changes, as described previously (5).

1 Abbreviations used in this paper: BMC, bone marrow cells; B6.Ec\textsuperscript{d}, I-Ec\textsuperscript{d} transgenic C57BL/6; gp70 IC, gp70-anti-gp70 immune complexes; HGG, human IgG.
Table 1. BMC Chimeric Mice

| Group | BMC donor | Recipient |
|-------|-----------|-----------|
| I*    | BXSB.Igh† male (Igh†) + BXSB-E-1 male (Igh‡) | BXSB female |
| II    | BXSB.Igh† male (Igh†) + BXSB male (Igh§) | BXSB-E-1 female |
| III   | BXSB.Igh† male (Igh†) + BXSB male (Igh§) | BXSB female |
| IV    | BXSB.Igh† female (Igh†) + BXSB-E-1 female (Igh§) | BXSB female |

* 2 mo after the reconstitution, the chimerism was checked by measuring serum levels of Ig allotype and by enumeration of IgM+ and IgMb+ allotype-positive circulating B cells. These analyses showed that both populations of donor B cells were equally repopulated in recipient mice (data not shown).

The present results demonstrate that the expression of the Eα chain transgene prevents the autoimmune syndrome of Ecx mRNA and β-actin mRNA levels, as determined by densitometric analysis on Northern blots, showed an ~20-fold-greater expression of Ecx mRNA in the spleen from the BXSB-E-1 mice than in BXSB.H-2b/d heterozygous mice.

Expression of the Ecx gene product was examined by the surface staining of spleen cells using an anti-IE mAb, Y-17, which recognizes combinations of Ecx and Eβ molecules of various haplotypes, including EcxEβb (16). Spleen cells from the BXSB-E-1 mice expressed the I-E molecule exclusively on surface IgM+ B cells at levels similar to those found on the spleen B cells of CBA/J (H-2k, I-E+) mice (Fig. 1 C). The transgenic mice contained, however, a significant percentage of I-E+ IgM+ B cells (about 15–20% of splenic B cells), which expressed the I-Aβ molecule at a density as high as that found on I-E+ IgM+ B cells (data not shown).

Such a disparate expression of I-E+ antigens among B cells has been previously noted in other Ecx transgenic mice generated using transgenes containing only a short 5′ flanking sequence of the Ecx gene (30). However, our Ecx transgene construct contains about 4 kb of 5′ flanking sequence, which is enough to allow an appropriate expression of Ecx mRNA and I-E α chain. In the spleens of B6.Eα transgenic mice generated using the same construct (14), no significant numbers of I-E+ IgM+ B cells were found (Fig. 1 C). The presence of I-E+ IgM+ B cells may thus be a peculiarity of the BXSB-E-1 mice or of mice with a lupus background. It is also possible that the I-E+ and I-E+ populations may represent two different subsets of B cells at different stages of activation or differentiation. In the transgenic mice, the I-E molecule was also present on a very small fraction of unstimulated monocytes, but on most IFN-γ-stimulated monocytes, as is also the case for normal I-E+ mice (data not shown). Immunofluorescence staining with the Y-17 anti-I-E mAb of thymus cryosections of these transgenic mice showed typical confluent staining of the medulla and reticular staining of the cortex (data not shown).

Expression of the I-E antigen in these transgenic mice was accompanied by a decrease in the Vβ5+ and Vβ11+ T cells, which potentially contain anti-I-E autoreactive T cells. Vβ5+ and Vβ11+ represented 1.48 and 2.91% of Thy-1+ cells from the BXSB-E-1 lymph nodes, as compared with 7.48 and 5.14%, respectively, in the BXSB nontransgenic I-E- littermates. In contrast, no differences were found in the percentages of Vβ6+ and Vβ8.2+ cells between the transgenic mice (10.55 and 12.45%, respectively) and their nontransgenic littermates (8.04 and 12.12%). The extent of this depletion of Vβ5+ and Vβ11+ T cells, presumably due to I-E expression in the transgenic mice, was comparable with that observed in I-E+ BXSB.H-2b/d heterozygous mice (7). The spleen cells of the BXSB-E-1 mice induced a significant proliferation of I-E+ BXSB lymphocytes in MLC (data not shown).

The lupuslike autoimmune syndrome developing in the male nontransgenic I-E- littermates was dramatically prevented in the male BXSB-E-1 transgenic mice. Whereas 50% of the nontransgenic I-E male littermates died of glomerulonephritis within the first 8 mo, with no survivors after 1 yr, none of the transgenic mice died within the first year (Fig. 2 A). Kidney histology at 8 mo showed in I-E- male mice a severe glomerulonephritis with increased mesangial and glomerular cellularity, obliteration of glomerular architecture, and tubular cast formation. In contrast, transgenic males exhibited minimal glomerular changes (Fig. 3). In correlation with the renal lesions, serum levels of total IgG, nephritogenic gp70 IC (6, 7, 31, 32) and IgG anti-DNA autoantibodies in the male transgenic mice at 6 mo were markedly lower than those of their male nontransgenic littermates (p < 0.001), and almost comparable with those of female BXSB mice (Fig. 2, B–D). Blood monocytosis, a unique abnormality characteristic of conventional BXSB male mice (33) was, however, unaltered in transgenic mice (percent Mac-1+ PBMC at 8 mo of age [mean of 5 mice ± 1 SD]; transgenic males, 20.6 ± 2.6%; transgenic females, 6.6 ± 0.9%; nontransgenic males, 19.5 ± 5.8%; nontransgenic females, 6.2 ± 1.2%). This indicates that monocytosis in BXSB males is neither a cause nor a consequence of the autoimmune syndrome, but rather is somehow related to the nature of the Yaa mutation. This also suggests that the expression of the I-E α chain transgene prevents the development of autoimmune responses, rather than the acceleration effect mediated by the Yaa gene in BXSB mice. This is further supported by our recent observation that the lupuslike autoimmune syndrome developing in (NZB × BXSB-E-1)F1 females in the absence of the Yaa gene is similarly inhibited by the presence of the Ecx transgene (Iwamoto, M., R. Merino, and S. Izui, unpublished observation).

The present results demonstrate that the expression of the I-E α chain transgene prevents the autoimmune syndrome.
in BXSB mice. This is reminiscent of the prevention of spontaneous autoimmune diabetes in NOD (I-E\(^{-}\)) mice by the expression of the I-E antigen through an I-E \(\alpha\) chain transgene (10–13). However, NOD mice (H-2\(^{b}\)) have a unique I-A\(^{NOD}\), made of an I-A\(\alpha\) chain and of a distinct type of I-A \(\beta\) chain (34). The mechanisms by which I-E expression protects NOD mice are still unclear, and protection is also afforded by the expression of I-A\(^{k}\) (35, 36). It has been speculated that expression of another class II MHC molecule in the cells of NOD mice prevents the peculiar self-antigen-presenting property of I-A\(^{NOD}\). In contrast, the I-A \(\alpha\) and \(\beta\) chains of BXSB mice are apparently conventional H-2\(^{b}\) class II MHC molecules. Expression of I-E molecules at the level provided by the H-2\(^{b}\) heterozygous state does not protect BXSB mice from their autoimmune syndrome (7), despite the fact that it is accompanied by a decrease in V\(\beta5^+\) and V\(\beta11^+\) T cells comparable with that observed in the BXSB-E-1 mice. This suggests that lack of the autoimmune syndrome in the BXSB-E-1 mice may be related to an unusually high level of I-E \(\alpha\) chains, as suggested by the very high levels of corresponding mRNA detected (probably related to the large copy number of E\(\alpha\) transgenes carried by these
Figure 2. (A) Cumulative mortality with glomerulonephritis in male BXSB transgenic (O) and nontransgenic (●) littermates (15 animals from each group). (B–D) Serum levels of total IgG, gp70 IC, and IgG anti-DNA autoantibodies in 6-mo-old BXSB transgenic and nontransgenic male and female mice.

Figure 3. (A) Representative histological appearance of glomerular lesions of kidneys from 8-mo-old BXSB nontransgenic male littermates showing increased glomerular cellularities and obliteration of the glomerular architecture. (B) Representative histological appearance of glomeruli from 8-mo-old BXSB transgenic males exhibiting minimal glomerular changes. Note a marked difference in the size of glomeruli between BXSB transgenic and nontransgenic littermates. The tissues were stained with periodic acid-Schiff reagent (×200).
mice). Preliminary findings indicate that the second transgenic line, BXSB-E-2, which also carries a high copy number of Eα transgenes and expresses Eα mRNA at a level similar to the BXSB-E-1 mice, fails to develop the autoimmune syndrome. An immune deficiency syndrome has been observed in mice bearing a high copy number (>50) of the Aβ transgene (37). It should be emphasized here that the BXSB-E-1 mice did not show any feature of immune deficiency, had an IgG level in male transgenic mice comparable with that found in nontransgenic BXSB female mice (Fig. 2B), and displayed a normal immune response against the T cell-dependent antigen HGG (serum IgG anti-HGG levels 14 d after aggregated HGG injection: BXSB-E-1, 528 ± 154 U/ml; BXSB, 555 ± 215 U/ml; IgG anti-HGG levels before immunization were <5 U/ml).

Overexpression of I-E α chain in these transgenic mice appears to lead to an increased formation of peptides derived from this chain which are presented in the groove of I-Aβ molecules. In mice bearing I-Aβ and I-E molecules, it has been shown that one of the major self-peptides presented by the I-Aβ molecules is derived from the I-E α chain. It appears that the I-Aα–I-E α peptide complexes are recognized by the Y-Ae mAb (22, 23). When this mAb was used to stain spleen cells of male mice derived from a cross between the BXSB-E-1 and BXSB.H-2d mice, surface IgM + B cells of mice bearing the Eα transgene expressed a higher density of the Y-Ae epitope than similar cells from nontransgenic littermates. This was not due to a difference in density of the I-Aβ molecule on these cells, since B cells from both types of mice expressed identical I-Aβ density (Fig. 4). The likeliest interpretation of this observation is that on splenic B cells of mice bearing the transgene, an increased fraction of the I-Aβ molecules contain in their groove the I-E α chain–derived peptide.

To explore whether an increased presentation of I-E α chain peptides by the I-Aβ molecule might prevent excessive activation of the B cells bearing these peptides, and thus explain the lack of autoimmune disease in the BXSB-E-1 mice, splenic I-E–IgM + and I-E+IgM + B cells isolated from 1-yr-old BXSB-E-1 male mice were fractionated and compared for their spontaneous Ig production. As shown in Fig. 5A, I-E– B cells secreted four to eight times more IgM and IgG than I-E+ B cells during a 24-h culture, suggesting that I-E+ B cells were selectively activated in vivo in the BXSB-E-1 mice. The smaller spontaneous Ig production of I-E+ B cells was not due to a general functional deficiency of these cells, since after stimulation with bacterial LPS, they were capable of producing IgM Abs at an even higher level than I-E– B cells (Fig. 5B). The relatively lower stimulation of I-E– B cells in vitro by LPS is consistent with the notion that these latter cells are selectively activated in vivo, as is the case for B cells derived from diseased lupus-prone mice (38).

It may be that a mechanism operates in transgenic mice overexpressing I-E α chains which inhibits the activation of B cells by some other indirect way. To explore this possibility, two types of chimeras were constructed, using nontransgenic or transgenic BXSB female mice lethally irradiated and reconstituted with BMC from transgenic and/or

![Figure 4](image-url) Increased surface expression of the Y-Ae epitope on surface IgM + B cells expressing the Eα transgene in BXSB mice. Spleen cells from 2-mo-old transgenic and nontransgenic BXSB male mice of H-2b/a haplotype, obtained from a cross between the BXSB-E-1 and BXSB.H-2d mice, were first stained with FITC-conjugated anti-mouse # chain mAb (LO-MM-9), and then incubated with biotinylated Y-Ae, Y-3P (anti-I-Ab), or Y-17 (anti-I-Eα) mAb, followed by PE-conjugated avidin. As controls, spleen cells from BXSB.H-2d male mice were stained with Y-Ae, Y-3P, or Y-17 mAb.

![Figure 5](image-url) In vitro spontaneous IgM and IgG secretion (A), and LPS-stimulated IgM production (B) by I-E+IgM+ and I-E–IgM+ B cells isolated from the BXSB-E-1 mice. For the spontaneous IgM and IgG secretion, 10⁶ I-E+IgM+ or I-E–IgM+ B cells sorted from spleen cells by a FACStar® were cultured for 24 h at 37°C in a humidified incubator containing 5% CO₂ in air. For the LPS-induced IgM production, 3 × 10⁶ I-E+IgM+ or I-E–IgM+ B cells were stimulated with LPS for 5 d. IgM and IgG concentrations in supernatants were determined by ELISA. Representative results of three separate experiments are shown.
nontransgenic BXSB male mice (Table 1). In these chimeras, the origin of B cells could be recognized because they bear different IgH allotypes. First, irradiated nontransgenic BXSB female mice were reconstituted with a mixture of BMC from nontransgenic (Igha) and transgenic (Igkb) male BXSB mice (group I). These mice developed lethal glomerulonephritis by 8 mo after the reconstitution as did BMC chimeras not involving transgenic bone marrow, i.e., female BXSB mice reconstituted with nontransgenic male BMC (group III). Significantly, IgH allotype analysis of the anti-DNA Abs revealed that they all originated from the nontransgenic male bone marrow population (Fig. 6). Second, irradiated BXSB transgenic female mice were reconstituted with a mixture of IgHa and Igkb BMC of nontransgenic males (group II). These chimeras had a glomerular disease of the same severity, and comparable levels of anti-DNA Abs bearing in this condition the two Ig allotypes. It should be noted that chimeras reconstituted with a mixture of BMC from transgenic and nontransgenic female mice (group IV) failed to develop a comparable autoimmune syndrome.

All this shows that two explanations for the prevention of the autoimmune syndrome in the transgenic mice can be ruled out: I-E expression by cells of the transgenic animal or resulting from the graft of transgenic BMC did not lead to the generation of CD8+ regulatory T cells "vetoing" the activation of autoreactive cells or to any form of clonal deletion of potential autoreactive T cells. It should be empha-

Figure 6. Serum levels of IgHa (□) and Igkb (○) anti-DNA Abs in four different groups of BMC chimeras (4 mo after reconstitution). Results are expressed in U/ml. The chimeras are those listed in Table 1.
sized that the presentation of I-E α chain peptides by the I-Ab molecule, as determined by the Y-Ae staining, was limited only to I-E+ B cells derived from the transgenic bone marrow population in transgenic and nontransgenic double BMC chimeras (group I; Fig. 7), and that these B cells produced far less anti-DNA autoantibodies than I-E+ B cells in these chimeras (group I; Fig. 6). These results are entirely consistent with the hypothesis that a lower activation of B cells bearing an I-E α chain peptide in their I-Ab molecule is the mechanism preventing autoimmunity in the transgenic mice.

Our results suggest a novel mechanism explaining how the expression of a transgene encoding the I-E α chain prevents autoimmune diseases. Since I-E α chain-derived peptides apparently have a high affinity for I-A molecules other than the I-Ab (39), this mechanism might also be responsible for the protection against the development of autoimmune diabetes by the expression of an Eαf transgene in NOD mice (10-13). Further understanding of the protective mechanism(s) conferred by the Eαf transgene may elucidate the molecular and cellular bases central to the development of murine SLE and possibly of autoimmune diabetes. These mechanisms could have clinical implications in the design of future therapeutic strategies with self-peptides in several autoimmune disorders.

We thank Drs. A. Y. Rudensky and C. A. Janeway, Jr. (Yale University School of Medicine, New Haven, CT) for providing us with the Y-Ae mAb; Drs. P. Vassalli, R. M. Zinkernagel, T. Seemayer, T. Fulpius, and T. Berney for critically reading the manuscript; Mr. D. Wohlwend (Cytofluorography Unit, Faculty of Medicine, University of Geneva) for help with flow cytometry; and Ms. Genevieve Leyvraz for histological preparations.

This work was supported by the Swiss National Foundation for Scientific Research, the Roche Research Foundation, the Japanese Ministry of Education, Science and Culture, and La Fondation Centre de Recherche Médicales Carlos et Elsie de Reuter.

Address correspondence to Dr. Shozo Izui, Department of Pathology, Centre Médical Universitaire, University of Geneva, 1, rue Michel Servet, 1211 Geneva 4, Switzerland.

Received for publication 29 April 1993 and in revised form 29 June 1993.

References

1. Murphy, E.D., and J.B. Roths. 1979. Autoimmunity and lymphoproliferation induction by mutant gene lpr, and acceleration by a male-associated factor in strain BXSB mice. In Genetic Control of Autoimmune Disease. N.R. Rose, P.E. Bigazzi, and N.L. Werner, editors. Elsevier North Holland, Inc., New York. 207-221.

2. Andrews, B.S., R.A. Eisenberg, A.N. Theofilopoulos, S. Izui, C.B. Wilson, P.J. MacConahey, E.D. Murphy, J.B. Roths, and F.J. Dixon. 1978. Spontaneous murine lupus-like syndrome. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198.

3. Eisenberg, R.A., S. Izui, P.J. MacConahey, L.M. Hang, C.J. Peters, A.N. Theofilopoulos, and F.J. Dixon. 1980. Male determined accelerated autoimmune disease in BXSB mice: transfer by bone marrow and spleen cells. J. Immunol. 125:1032.

4. Hudgins, C.C., R.T. Steinberg, D.M. Klinman, M.J.P. Reeves, and A.D. Steinberg. 1985. Studies of consomic mice bearing the Y chromosome of the BXSB mouse. J. Immunol. 134:3849.

5. Izui, S., M. Higaki, D. Morrow, and R. Merino. 1988. The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW × C57BL/6)F1 male mice, but not in C57BL/6 male mice. Eur. J. Immunol. 18:911.

6. Merino, R., T. Shibata, S. de Kossodo, and S. Izui. 1989. Differential effect of the autoimmune Yaa and lpr genes on the acceleration of lupus-like syndrome in MRL/MpJ mice. Eur. J. Immunol. 19:2131.

7. Merino, R., L. Fossati, M. Lacour, R. Lemoine, M. Higaki, and S. Izui. 1992. H-2 linked control of the Yaa gene-induced acceleration of lupus-like autoimmune disease in BXSB mice. Eur. J. Immunol. 22:295.

8. Mathis, D.J., C. Benoist, V.E. Williams II, M. Kanter, and H.O. McDevitt. 1983. Several mechanisms can account for defective Eαf gene expression in different mouse haplotypes. Proc. Natl. Acad. Sci. USA. 80:273.

9. Oliveira, D.B.G., and N.A. Mitchison. 1989. Immune suppression genes. Clin. Exp. Immunol. 75:167.

10. Nishimoto, H., H. Kikutani, K. Yamamura, and T. Kishimoto. 1987. Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice. Nature (Lond.). 328:432.

11. Uehira, M., M. Uno, T. Kühn, H. Kikutani, K. Mori, T. Inomoto, T. Ueda, J. Miyazaki, H. Nishimoto, T. Kishimoto, and K. Yamamura. 1989. Development of autoimmune insulitis is prevented in Eαf but not in Aβ4 NOD transgenic mice. Int. Immunol. 1:209.

12. Böhme, J., B. Schuhbaur, O. Kanagawa, C. Benoist, and D. Mathis. 1990. MHC-linked protection from diabetes dissociated from clonal deletion of T cells. Science (Wash. DC). 249:293.

13. Lund, T., L. O'Reilly, P. Hutchings, O. Kanagawa, E. Simpson, R. Gravely, P. Chandler, J. Dyson, J.K. Picard, A. Edwards, et al. 1990. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A β-chain or normal I-E α-chain. Nature (Lond.). 345:727.
14. Yamamura, K., H. Kikutani, V. Folsom, L.K. Clayton, M. Kimoto, S. Akira, S. Kashiwamura, S. Tonegawa, and T. Kishimoto. 1985. Functional expression of a microinjected Eo~ gene in C57BL/6 transgenic mice. Nature (Lond.) 316:67.
15. Hogan, B., F. Constantini, and E. Lacy. 1986. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 152–203.
16. Lerner, E.A., L.A. Matis, C.A. Janeway, Jr., P.P. Jones, R.H. Schwartz, and D.B. Murphy. 1980. Monoclonal antibody against an Ir gene product? J. Exp. Med. 152:1085.
17. Maniatis, T., E.F. Fritsch, and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 382–389.
18. Hyldig-Nielsen, J.J., L. Sehenning, U. Hammerling, E. Widmark, E. Heldin, P. Lind, B. Servenius, T. Lund, R. Flavell, J.S. Lee, et al. 1983. The complete nucleotide sequence of the l-Ee~ immune response gene. Nucleic Acids Res. 11:5055.
19. Chirgwin, J.M., A.E. Przybyla, R. MacDonald, and W.J. Rutter. 1979. Isolation of biologically active ribonuclease acid from sources enriched in ribonucleases. Biochemistry. 18:5294.
20. Bazin, H., F. Cormont, and L. De Clercq. 1986. Purification of rat monoclonal antibodies. Methods Enzymol. 121:638.
21. Janeway, C.A., Jr., P.J. Conrad, E.A. Lerner, J. Babich, P. Wettstein, and D.B. Murphy. 1984. Monoclonal antibodies specific for Ia glycoprotein raised by immunization with activated T cells: possible role of T cellbound Ia antigens as targets of immunoregulatory T cells. J. Immunol. 132:662.
22. Rudensky, A.Y., P. Preston-Hurlburt, S.C. Hong, A. Barlow, and C.A. Janeway, Jr. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature (Lond.). 353:622.
23. Rudensky, A.Y., S. Rath, P. Preston-Hurlburt, D.B. Murphy, and C.A. Janeway, Jr. 1991. On the complexity of self. Nature (Lond.). 353:660.
24. Springer, T., G. Galfré, D.S. Secher, and C. Milstein. 1979. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur. J. Immunol. 9:301.
25. Schüppel, R., J. Wilke, and E. Weiler. 1987. Monoclonal antiallotype antibody towards BALB/c IgM. Analysis of specificity and site of a V-C crossover in recombinant strain BALB-Igh-V~/-Igh-C~. Eur. J. Immunol. 17:739.
26. Nishikawa, S., Y. Sasaki, T. Kina, T. Aragai, and Y. Katsuma. 1986. A monoclonal antibody against Ig~64 determinant. Immunogenetics. 23:137.
27. Garnier, J.L., R. Merino, M. Kimoto, and S. Izui. 1988. Resistance to tolerance induction to human gammaglobulin (HGG) in autoimmune BXSB/MpJ mice. Functional analysis of antigen-presenting cells and HGG-specific T helper cells. Clin. Exp. Immunol. 73:283.
28. Merino, R., L. Fossati, M. Lacour, and S. Izui. 1991. Selective autoantibody production by Yaa~ B cells in autoimmune Yaa~Yaa~ bone marrow chimeric mice. J. Exp. Med. 174:1023.
29. Ledbetter, J.A., and L.A. Herzenberg. 1979. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol. Rev. 47:63.
30. Burkly, L.C., D. Lo, C. Cowing, R.D. Palmiter, R.L. Brinster, and R.A. Flavell. 1989. Selective expression of class II Ee~ gene in transgenic mice. J. Immunol. 142:2081.
31. Yoshiki, T., R.C. Mellors, M. Strand, and J.T. August. 1974. The viral envelope glycoprotein of murine leukemia virus and pathogenesis of immune complex glomerulonephritis of New Zealand mice. J. Exp. Med. 140:1011.
32. Izui, S., P.J. MacConahey, A.N. Theofilopoulos, and F.J. Dixon. 1979. Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. J. Exp. Med. 149:1099.
33. Wofsy, D., C.E. Kerger, and W.E. Seaman. 1984. Monocytosis in the BXSB model for systemic lupus erythematosus. J. Exp. Med. 159:629.
34. Acha-Orbea, H., and H.O. McDevitt. 1987. The first external domain of the nonobese diabetic mouse class II I-A~ chain is unique. Proc. Natl. Acad. Sci. USA. 84:2435.
35. Miyazaki, T., M. Uno, M. Uehira, H. Kikutani, T. Kishimoto, M. Kimoto, H. Nishimoto, J. Miyazaki, and K. Yamamura. 1990. Direct evidence for the contribution of the unique I-A~NO~ to the development of insulitis in non-obese diabetic mice. Nature (Lond.). 345:722.
36. Slattery, R.M., L. Kjer-Nielsen, J. Allison, B. Charlton, T.E. Mandel, and J.F.A.P. Miller. 1990. Prevention of diabetes in non-obese diabetic I-A~ transgenic mice. Nature (Lond.). 345:724.
37. Gilfillan, S., S. Aiso, S.A. Michie, and H.O. McDevitt. 1990. Immune deficiency due to high copy number of an AB~ transgene. Proc. Natl. Acad. Sci. USA. 87:7319.
38. Cohen, P.L., and M. Ziff. 1977. Abnormal polyclonal B cell activation in NZB/NZW F1 mice. J. Immunol. 119:1534.
39. Hunt, D.F., H. Michel, T.A. Dickinson, J. Shabanowitz, A.L. Cox, K. Sakaguchi, E. Appella, H.M. Grey, and A. Sette. 1992. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-A~. Science (Wash. DC). 256:1817.